INTRODUCTION
Original business models emergence in new industries and become rapidly iconic.
Those of firms that have shaped the biotech industry (such as Millennium, Celera Genomics or Genentech) revolutionised the environment by inventing unprecedented ways to bridge upstream research, venture capitalists and large firms. However the most successful biotech companies have generated revenues by implementing several different business models simultaneously to serve different customers. But the portfolio of business models underlying these success stories have been generally hidden by the most emblematic model. Many firms manage a portfolio of business models to develop the market value of their core competencies and to generate revenue streams to balance time-to-market pressure, risks, interdependency and expected returns.
The article examines the biopharmaceutical industry (i.e. pharmaceutical and biotechnology companies) to analyse how biotech firms bridge core competencies and business strategies to develop business models. It argues that firms can combine different business models to deliver value simultaneously to different markets. Teece [1] defines a business model as the 'way in which the business enterprise delivers value to customers, entices customers to pay for value, and convert those payments to profit', and we define a portfolio of business models as the range of different ways a firm delivers value to its customers to ensure both its medium term viability and future development. Using four in-depth case studies we explore how biotech firms use different business model designs to generate added value and profit from their core competencies, and balance time-to-market, risks, interdependency and expected returns to create medium term value and longer term viability by organising and combine these models at the firm's corporate business architecture level.
The article contributes to current learning in three ways: first of all, it positions the notion of 'Business model' as an intermediary concept bridging firms' core competencies and business strategy. Second, it introduces and discusses the notion of a portfolio of business models as a way to articulate and finance the firm's activities in the medium run and to ensure idiosyncrasy to protect its future health. Third, it analyses how young firms manage to build simultaneously a short term business and invest into their future business.
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The first part of the article explores the relationship between core competencies and business models, i.e. ways to create and capture value based on core competencies. The data and methodology section then describes the four case studies of firms and their six business models, while the third section discusses management of a business model portfolio.
FROM BUSINESS MODEL TO BUSINESS MODEL PORTFOLIO
Fab-less, e-commerce, commercialisation of science, two sided markets: these new labels describe new ways to organise activities within firms and to reposition businesses to add value for customers and to generate profit for the firm. All firms implement business models, and many implement several simultaneously to deliver value for different categories of consumers and to balance revenue stream, risks and interdependencies with other actors. At the corporate level, firms may manage such portfolios of business models to generate value from their core competencies to address different customers. We first discuss the notion of the business model, considering its two fundamental dimensions: as a concept and as a tool. Business models are then characterised by four criteria (time-to-market, risk, interdependencies and expected returns). The section then introduces the concept of the business model portfolio as combining these four criteria to provide the firm with a sustainable revenue stream.
The Business Model -a Bridge between Business Strategy and Core

Competences
The concept of business model is an intermediary concept between core competencies and business strategy, linking internal appraisal of organisational capabilities and the strategic positioning on evolving markets. Core competencies (or core capabilities) refer to a firm's fundamental ability for undertaking specific activity, to create a value proposition for the ultimate customer or to deliver that value more efficiently. Hamel and Prahalad [2] argue that capabilities must be appraised in comparison with those of other firms, while Leonard-Barton [3] [4] and idiosyncratic nature of firm activity, while business model focuses on a specific activity. As business strategy, business model does not cover the entire company, and firms may be involved exploiting several business models. The concept of business model covers not only the firm's interaction with the customers but also how it organises to benefit from the value delivered. Business model bridges the internal appraisal of core capabilities to understand how the firm builds its uniqueness in the combination of resources and business strategy, which studies how firms create and maintain competitive advantage. The concept of business model articulates the creation and value delivering for the customer, with the organisational capabilities of the firm to differentiate strategies [5] .
The Business Model as Practical Tool for Managers
Morgan and Baden-Fuller [6] argue that business models are not only a concept but also a practical tool for managers. As in economics, models are used in management to make up for the lack of knowledge, as a tool to inquire into how firms work, and to figure out relationships between their different elements so as to imagine how they might work. Business models illustrate relations between value creation and value capture activities for strategists, questioning existing value chains, and articulating possible opportunities for core competencies within value chains.
This can be particularly valuable when industries change rapidly. As an industry matures, its value chains can be profitably de-integrated, allowing greater hal-00430782, version 1 -24 Nov 2010 specialization of inputs and outputs and leading to improved efficiency and greater speed to market [7] , and Schweitzer [8] has identified this disintegration of the value chain as offering opportunities for new business models. Norman and Ramirez [9] also propose that exploding the rigid value chain into a constellation of actors can allow it to be reconfigured; generating new ways to create value and leading to contestable markets [10] . Studying the origins of the biotech industry, McKelvey [11] considered the early stage strategy of Genentech, pointing out the de-integration of the value chain in the pharmaceutical industry during the 80s. The introduction of biotechnologies has opened up fresh opportunities for new entrants to propose alternative business models, to differentiate their offerings and to deliver added value to customers.
The first category of the Business Model as a tool deals with the production of newness, technological innovation or in ways of doing business. New technologies may require new business models to capture value, as in the biotech industry where scientists have been able to create value from the production of scientific results, extending the existing pharmaceutical industry value chain backwards towards basic scientific research. Thus the business model can be a leverage tool to question the existing value chain and to identify (new) high added value positions in the value chain. Or the 'newness' may involve new ways to deliver existing technologies: the advent of the Internet has changed the existing value chain of computer production and resellers by creating direct communication between producers and consumers [12] , as was the case, for example, with Dell, when direct internet selling enabled Dell to both enhance the value proposition for its consumers and the value capture opportunities for the firm.
The second category of tool deals, with the dilemma of rent creation and appropriation. Different actors or firms are involved in the value creation process, all of which seek to generate rents from the value created which, (as Pisano [13] and Durand et al. [14] point out) inevitably generates tensions. In the biopharmaceutical industry, where firms develop new drugs and new techniques based on upstream research, those closer to the markets and to customers are better positioned to capture rents. Most of biotech SMEs have not been able to capture the value they anticipated, and rent appropriation levels are lower than expected. As business models focus on how to deliver value to markets, they can allow the firm to differentiate their strategic hal-00430782, version 1 -24 Nov 2010 value creation and rent appropriation action. When markets seem incontestable, incumbents dominate the competition and value-chain positions seem to be 'locked', thinking in terms of business models offers a way to re-establish contestability by inventing new ways to compete, be they alternative ways to deliver products or services, or by developing new technological innovations or adopting new positions in the value chain.
Four Criteria to Characterise Business Models
Strategists and strategic authors have tended to characterized business models by pointing out 'polar' positions: service oriented firms with short time to market and low expected returns versus product oriented firms with longer times to market and high expected returns; [15] [16] , alliances versus final consumers [17] ; commercialization of science as intermediary services versus commercialization of products; direct on-line commercialization versus shops [18] [19], Chesbrough and Rosenbloom [4] and Voelpel et al. [20] . However, when we review the list of criteria used to characterise business models, we can identify four dimensions as synthesizing the previous works on high tech business models: time to market, technological/financial risks, interdependencies amongst actors and expected returns.
Time to market characterises how and when a product or service reaches the market.
It influences the business logic and is one of the primary factors in establishing competitive edge [21] . Strong market pressures tend to force firms to reduce their R&D time horizons to lessen their time to market [22] . Time-to-market also determines the firm's ability to finance its day-to-day activities before cash can be generated. Cash is burnt before product or service launch to market: if times-tomarket are long, firms' activities must be funded by their other activities, or by venture capital. Time-to-market also affects appropriation levels -investors financing firms involved in R&D will appropriate part of the eventual rents as their returns, and their slice of the action will increase the longer the product or service takes to come to market.
Risks also affect the firm's business logic, and have both technological and financial dimensions [23] . The more radical the innovation, the more the firms runs the risk that, in the end, it will have nothing to take to market that time, energy and reputation will have been wasted and there will be nothing to appropriate from which to fund hal-00430782, version 1 -24 Nov 2010 future activity, or to repay investors. In the case of the biopharmaceutical industry the technological dimension also concerns drug failure: drug may fail after early or advanced clinical trials. Risks are also closely linked with the time frame required for ramp-up -longer timescales heighten both dimensions of risk.
Interdependencies with other organisations are related to the levels of specificity of the firm activity. Following Afuah and Utterback [24] work about industry life cycle, the power of suppliers is relatively low during the emergence phase as specific assets have been developed. As the market increases and firm specificity grows, its relations with its suppliers and producers (and even consumers) will increase, and it will adopt strategic behaviour and adapt its business model to manage these interdependencies.
When interdependencies are high and the firm needs additional competencies to perform its activity, alliances may be formed, complicating both its control of the activity and its ability to appropriate rents. When its exchanges with other actors remain non-specific, interdependencies are lower and the firm is better position to appropriate the generated rent.
Expected
Returns are the anticipated level of value generated by the activity, and the promises made by the firm to its shareholders in terms of the return they can expect on their investments. The level of the firm's returns will depend upon the size of the targeted market, the amount of investment and the degree of its success in appropriating rents.
Any business model can be characterised on these four dimensions, which are all interrelated. The drug development business model requires usually long investment before the launch on the market; it is highly risky and often requires firms to ally to finance and pursue their activities, and such development activity is only possible because expected returns are very high. At the opposite end of the scale, a service business model is characterised by shorter time to market, lower investment needs and smaller expected returns, which can enable the firm to carry through development internally. At the corporate level, firms often develop several business models simultaneously to balance these four characteristics and run multiple activities over on the medium term, the returns from some financing the others. Portfolio Display, etc.) and on the management of risks in corporate innovation [25] .
Business Model Evolution in the Biopharmaceutical Industry
The biopharmaceutical industry has been very inventive in terms of business models.
The biotech industry has been the setting for much development in the commercialisation of science, leading to the increasing role of university patenting [26] . and has also seen value chain de-integration opening up many opportunities for developing new activities.
But it is also one where promises have been so high for so long, but where results have remained far below expectations [13, 27] . Firms' managers -and the industry as a whole -promised to shorten drug development process, from heuristic to rationale drug development. Biotechnology promised personal medicine and affordable drugs for patients, personal genetic diagnostics and increased prevention capabilities for genetic diseases, and big returns on investments for biotech firms and investors. But after almost thirty years, Pisano has shown how the industry's structure is flawed:
'islands of expertise' need to be brought together to develop a medicine; while scientific knowledge is being created, new drugs discovered and process development improved, appropriating rents remains problematic [14] ; and despite all the industry's explorations and experiments with new business models, none has yet appeared as a dominant design.
In the modern sense of biotechnology, the industry appeared in the mid 1970s as the development of genetic engineering and monoclonal antibodies disrupted the traditional drug development process that was essentially based on the synthetic organic chemistry heuristic [27] . The core competences of pharmaceutical firms were their accumulated know-how and their access to patients to perform trials. The drug development value chain is based on a drug development route that follows five well known (usually consecutive) steps leading to the market: research and drug discovery, preclinical studies (animal tests), phase I (early human clinical trials), phase II (medium-sized human tests) and phase III trials (large human tests).
However, since 2000, the value chain has been de-integrated, and a new form of networked industrial structure involving highly specialised actors is emerging [28] .
Large pharmaceutical firms fill gaps in their R&D pipelines and research portfolios by collaborating with smaller firms, buying or co-developing drugs at any stage of development [27] . And biotechnology developments have focused not just on products, but also on specific and high value added service elements.
DATA COLLECTION AND ANALYSES
This section describes the generic core biotech industry competencies and presents two levels of analysis -the business model and the firm. Case studies of European biotech firms and their business models are examined to analyse the business models firms employ to put their core competencies into action to deliver value, so as to illustrate how they build business model portfolios at the corporate level. Data collection was organised to gather data at two levels: business models and firms.
First, sixteen experts of the European biopharmaceutical industry were interviewed to map out the core competencies along the drug development value chain and understand the basis underlying today's business models. Second we conduct four case studies of European biopharmaceutical SMEs to gain fine grained analysis of business models portfolio, showing how young companies employ different models to optimise the allocation of their resources.
Three Core Competencies
Experts have identified three core competencies in the contemporary biotech industry focused on the discovery and ownership of candidate drugs;  The architecture and recombination of knowledge from the biotech and biopharmaceutical industries, in which firms reorganise their knowledge to detect opportunities aiming to mobilise, combine or benefit from external knowledge. This competence focuses on the ability of the firm to orchestrate knowledge from its partners rather than on its own ability to develop new drugs, and may involve value chain reconfiguration;  The processes optimization competence. As biotechnolgies matures, costs become more significant, and the more efficient industrialisation of services, R&D or production processes, or the improvement of linkages between the two, become more important. Table 1 evaluates the characteristics of the different business models based on these core competencies (for more details about the evaluation of the characteristics see appendix 3). The drug discovery core competence is characterised by a long time needed to work through the development route value chain, levels of risk and interdependency are high, because outcomes cannot be guaranteed but high levels of financial investments will be required whether the searches end in success or failure and the focal firm will need external expertise -but expected returns can be very high: launching a successful new drugs onto the market will yield allow good returns and margins. The knowledge architecture core competence involves medium time to market and risks,
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and while interdependency with other firms is high, so are the expected returns. The process optimisation core competence generally involves short times to market with low or medium risks and requires few interdependencies, but does not promise high returns. Based on each core competence, firms adapt, design and amend business model to improve their characteristics: reducing time-to-market for drug discovery, managing interdependencies and risks for knowledge architecture more effectively and increasing the expected returns to process optimisation.
Business Models at the Firm Level
To describe business models and they are enacted within a firm, we focus on four case studies. As the post-2000 period has been characterised by the increasing specialization of business models, we limited our sample to firms founded since 2000. We employed the technique of searching for polar types, where an important guideline is to select cases that contradict patterns noted in prior cases study [29] . So we sought companies with business models that differed substantially from the fully integrated pharmaceutical company business model [28] that has been studied often.
Four European biopharmaceutical companies suited these criteria and agreed to be part of the study.
Data collection began with meeting the founders of the company and questioning them about the company's history, its activities and markets. Each interview lasts at least two hours and generated an overall view of the company's bundle of activities.
(A high level of confidentiality was assured to secure access to strategic information.)
The second phase was dedicated to analysing documents and cross-referencing internal sources against information from specialized press and website sources. The third phase comprised in-depth individual interviews lasting an hour and half with the CEO, chief scientific officer (CSO) and chief financial officer (CFO) of each firm, focusing on the financing model, the structure of costs, investments, scientific challenges, times to market and the revenue model. We also asked about the firm's partners and their levels of involvement, and about intellectual property issues around the firm's products or services, parameters which help us determine the company's business models and the way its portfolio is managed.
We first analysed core competences in action i.e. how firms designed effective business models to match customer expectations, looking at how the firm adapted its
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business model based on the three generic core competences as well as the firm's positioning on the value chain.
The second level of analysis was of the firm as a whole, to discover how it combined its different business models to implement its overall strategy. Three of the four firms were managing a portfolio of different business models, while the other replicated the same business model in order to maximise its value proposition: we study how each enacts its business models to generate and appropriate rents.
Analyses of Four Cases
OphSmart is a small company of thirty people founded in 2005 which develops a pipeline of products all focusing the ophthalmology therapeutic domain. OphSmart has two core competencies: drug discovery and knowledge architecture. In the drug discovery realm, OphSmart specialises in upstream collaborations with universities to renew its own pipeline. In terms of knowledge architecture, OphSmart seeks to shorten drug development times by repositioning drug candidates in ophthalmology.
These drugs are bought from other companies. Then OphSmart manages a network of firms to develop the molecules: it does not invest in manufacturing or laboratories,
OphSmart externalises every step of the drug development. It therefore runs three interrelated business models concurrently: collaboration with universities to discover molecules; repurposing of existing molecules to its therapeutic domains and organising networks to form a virtual company. Each time, the business logic is based on a dense network of contacts, built up over the projects and over the previous deep involvement in the industry of the management team.
Emics is a small company run by a team of three people which, since its founding in 
ADAPTING BUSINESS MODELS AROUND THREE CORE COMPETENCIES
The relationships between core competencies and business models are discussed first, followed by descriptions of how firms organize their business model portfolio.
Drug Discovery Core Competence
Such firms share risks with partners and aim to shorter the time to market by using business models different to the traditional business model for drug development. managing an array of partners brings expertise at the very needed moment and reduces investments confronting to the fully integrated pharmaceutical company.
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Process Optimization Core Competence
The core competence of process optimisation deals with optimising drug development processes. R&D or production processes can be made more efficient, or linkages between the two improved. Optimisation concerns services, research tools or production. In our firm we found two business models built on this core competence.
Technology platform activities include engineering and technological developments, molecule optimisation, screening, etc., and generally focus on the early drug development phases. They are many forms of platforms (such as open technology platforms, proprietary platforms, etc.) but broadly speaking they provide technological developments through service contracts or act as co-developers at some product development steps. This technological development activity creates value, which is then captured through the price of the service or the success of the drug or technology co-developed. The time-to-market is short to medium, and risks are low (in the simpler service case) or medium for co-development activities.
Interdependency and expected returns are also low or medium, again depending on the form (contract or co-development partnership) of the activity.
Contract manufacturing organisations (CMO) is a business model which is based on
optimisation processes for the production of preclinical, clinical and final batches for other actors of the value chain.
Activities in business models based on process optimisation are not core to the main value chain, but provide services for value chain actors. Firms provide the same kind of actions for any product, corresponding to the 'layer player' archetype [8] . With shorts time to market these business models generate cash in the short term. Table 2 presents the adapted business models based on the three core competencies in the biotech industries and observed in practice. Each of the business models improves at least one of the criteria: reducing risk for collaboration in discovery, maintain high returns with limited risks for business models based on knowledge architecture and shortening time to market for optimisation business models. All the firms have developed different activities within the same industry, organising their business models to align their organisational capabilities to address specific customers and to extract added value from their core competencies. 
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BALANCING A BUSINESS MODEL PORTFOLIO
In practice these four small European biopharmaceutical companies may use more than one competence to position themselves on the value chain and may thus employ several business models. The business architectures of OphSmart, Emics and OpteX involve managing several business models simultaneously, with two core competencies in each case. A key issue for these companies is to try to moderate time to market and risks in order to attract investors, redeploying or extend the same business logic towards additional costumers. Betwin is the only one which reuses the same core competence into different markets.
OphSmart's portfolio mixes long and medium times to market, medium and low risks, high and low needs for alliances and high expected returns. Its three business models enable it to balance the time to market, risks and interdependency to keep returns on investment high. Its activities are also linked: whether a molecule is repurposed or discovered in-house, it will be developed via the virtual development business model. OphSmart redeploys its core competencies to capture value at different stages of the value chain. Emics runs two business models based on one core competence each, its two core competences, allowing it to balance time to market and risks because, although these two criteria should be high (as in its hal-00430782, version 1 -24 Nov 2010
discovery-based business model), they are lowered by its knowledge architecture competence. OpteX's business models do not promise high returns, but times to market are short and risks low, allowing it to generate short-term rents successfully.
OpteX originally used its core process optimisation competence to manage two business models that were internally coherent -the technology platform and contract manufacturing organization (CMO) activities followed the same sequential drug development steps -and re based on the same production optimisation business logic. But the firm also detected the opportunity of technology brokering on the value chain using the strong network of clients developed via its original business modelsthey naturally became both sources and customers for its new technology brokering model, with OpteX acting as a link between them. OpteX was able to align this new activity coherently both with its business sector and with its current activities. Once its three business models are stabilized the company will be able to take more codevelopment risks in its technology platform business model.
Finally, Betwin has one business model which it has replicated continuously, which, because it focuses on new opportunities created by intermediary markets, assures it of a medium time to market with medium risks and promises high returns to investment.
Betwin's founders recognised this new opportunity on the value chain, and adapted their business logic specifically to match this profit zone. Betwin has developed capabilities to detect molecules and to organise networks to deliver them. So the firm is organized on a virtual business model to buy early developed molecules to create value for its customers.
These four companies show that business models can be balanced to insure short or medium time-to-market, which is important as it is difficult for small companies to survive the long period -of maybe twelve years -without turnover and profit involved in longer-term models. Long time lags between investment and the first generation of turnover can often lead to rejection by investors, whereas being able to promise mid-term rents can reassure shareholders that they will see a return on their investment within five years. Firms invest in different business models to limit the level of risk and to speed up time-to-market for part of their activities. Firms with drug discovery as their core competence need to benefit from additional competencies to develop new drugs, so they are often involved in dense networks to perform their activities, and thus need to be able to manage interdependencies effectively. For firms investing in knowledge architecture as a core competence, their activity is to manage linkages with other actors, and they are thus also highly interdependent. Finally, firms that invest in optimisation, and whose business is to optimise other actors' production processes, so they, too, depend on others. These business model portfolios portray an interesting link between with risk and time-to-market: while product companies promise a high value, alternative business models are used to balance risk and time-to-market values.
So (compared to fully integrated pharmaceutical companies) these small firms have found ways to promise high value, medium risk and acceptable times-to-market. 
Strategies with Business Model Portfolio
Business models bridge management's expectations about customer needs and their core competencies. In maturing industry, specialisation and division of work within the value chain create opportunities for firms to design new business models and new value propositions. This article argues that a core competence can be transformed in several business models, and shows how, in the biopharmaceutical industry, firms have found numerous ways to translate their core competencies into activities to address costumers at different stages of the value chain. The business model as a concept linking core competencies, the value chain and consumers' needs can help promote strategic thinking from both the internal and external perspectives.
The existence of a portfolio of business models reveals the firm's maturity as it develops from the start-up phase (based on a single business model) to managing a more complex architecture designed to reduce risks and maintain equilibrium across a variety of activities. Case studies reveal that firms tend to add activities that relate to some aspect of their existing ventures, either based on the same core competence or developed to take exploit certain common technological and market characteristics. Firms can have one or more core competences enacted within different business models, reveal the coherence of their activities [31] . Different business models can be driven by similar business logics, when they extend the market niche addressed or the services or products offered to similar audiences.
Companies may run parallel, vertical integrated business models to cover more sectors of their value chain, and their consecutive articulation can allow the firm to benefit from synergistic effects, adding more value for customers and (hopefully) more profit for the firm. Table 3 side it assesses the degree of relatedness between existing activities within the firm. interdependencies and expected returns.
Business models Portfolio and Corporate Strategy
Business model and business strategy are deeply interrelated. They both focus on one activity and key customers. As a key component of its competitive strategy, a firm's business strategy aims to identify growing markets and to position firm activities within those markets. Business models then describe how firms develop organisational capabilities to benefit from these promising markets, so connecting internal capabilities with ways to address market niches and costumers. Business 
CONCLUSION
A business model can be seen as an intermediary tool between corporate and business strategies, and defined as articulating a value proposition for an evolving value chain, and the way in which the firm delivers product or services to create and then appropriate value. A firm's business strategy determines how it uses its resources, satisfies its long-run objectives, and defines the implementation of its corporate strategy [32] . The business model articulates both the internal and external dimensions, bridging between capabilities and competences, and value chains, markets and customers, focusing on the coherence of activity within both the industry and the firm.
A biopharmaceutical company providing R&D services and production of early clinical trials will segment its business strategy depending on the market: e.g.
proteins vs. monoclonal antibodies. But the business model view considers two business models: the contract research organization and the contract manufacturing organization. Although the markets are different, the activities are closely linked and the company will enhance its coherence and synergy effects if it manages its business models to benefit from these effects.
For managers, the concepts of business models and business model portfolios are particularly useful to understand that firms can pursue multiple business models within one strategy. This meso-level analysis generates descriptions that allow strategists to better position the firm activities. In addition, industry matures, and its activities, actors and their relationship are continually evolving. To put it simply, the notion of the business model which articulates activities within the firm and its relation with customers is particularly suited to changing environment. Different ways may be explored, from core competence extension to duplication in other fields. 
Respondent 10
European biotechnology medium company CEO manages a biopharmaceutical company dedicated to the discovery and development of products innovation for a specific disease.
Respondent 11
European biotechnology medium company CEO who manages a biopharmaceutical company founded in 1990 dedicated to the development of vaccines against infectious diseases.
Respondent 12
European biotechnology medium company CSO is the co-founder of a biopharmaceutical company, and manages its scientific programs, collaborations and participations in European consortia.
Respondent 13
European biotechnology medium company Chief Scientific Officer in a company developing vaccines having started his career in a prestigious academic laboratory.
Respondent 14
European biotechnology medium company COO of a biopharmaceutical company dedicated to product discovery and development. He started as a scientific researcher, and has since been involved in the management of many companies.
Respondent 15
European biotechnology medium company CFO for a product-based firm. He has worked in the biotechnology industry for many years and conducted two Initial Public Offerings in different companies Respondent 16 CFO of European biotechnology medium company European biopharmaceutical company quoted on the NASDAQ.
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Appendix 2: Extracts of interviews that helped us to determine the three core competences present on the drug development value chain. When the core activity of the firm depends upon alliances with other partners.
Expected returns Low Medium High
Expected returns are the turnovers that will be created by the activity. The maximum is the turnover produced by a blockbuster drug. In comparison the price of a service is a low return.
Low value added services.
High value added services or pharmaceutical production.
Drugs on the market. hal-00430782, version 1 -24 Nov 2010
